close

Вход

Забыли?

вход по аккаунту

?

arclin%2Facx089

код для вставкиСкачать
Archives of Clinical Neuropsychology 32 (2017) 906–916
Considerations for Clinical Neuropsychological Evaluation
in Amyotrophic Lateral Sclerosis
Susan C. Woolley1, Beth K. Rush2,*
2
1
Sutter Pacific Medical Foundation, CA, USA
Mayo Clinic Florida, Department of Psychiatry and Psychology, 4500 San Pablo Road, Jacksonville, FL 32224, USA
*Corresponding author at: Mayo Clinic Florida, Department of Psychiatry and Psychology, 4500 San Pablo Road, Jacksonville, FL32224, USA.
E-mail address: rush.beth@mayo.edu (B.K. Rush).
Editorial Decision 25 August 2017; Accepted 14 September 2017
Abstract
The clinical neuropsychologist has the opportunity to be uniquely involved in the evaluation and treatment of individuals with amyotrophic lateral sclerosis (ALS). We review the current literature that defines cognitive and behavioral symptoms in ALS, including current
knowledge of the neuropathological and genetic underpinning for these symptoms. There are unique considerations for clinical neuropsychological evaluation and clinical research in ALS and we highlight these in this review. Specifically, we shed light on special factors that
contribute to our understanding of cognitive and behavioral impairment in ALS, including co-morbid symptoms, differential diagnosis, and
considerations for longitudinal tracking of phenotypes. We discuss the rationale for proposing a specific approach to such as cognitive
screening, test selection, response modality consideration, and test–retest intervals. With this didactic overview, the clinical neuropsychologist has the potential to learn more about the heterogeneous presentation of motor and neuropsychological symptoms in ALS. Furthermore,
the reader has the opportunity to understand what it takes to develop a valid assessment approach particularly when the phenotype of ALS
remains undefined in some regards. This clinical practice review sets the stage for the clinical neuropsychologist to further contribute to our
clinical and scientific understanding of ALS and cognition.
Keywords: Amyotrophic lateral sclerosis; neuropsychological assessment
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative neuromuscular disease first described by Charcot in
1869. In the U.S., it is commonly referred to as Lou Gehrig’s disease, and throughout Europe, it is characterized as a form of
motor neuron disease (MND). Defined by the progressive death of motor neurons in the brain and spinal cord, initial symptoms can include muscle atrophy, weakness, fasciculations, or spasticity. Symptoms can begin unilaterally in one limb, with
disease spread across the midline to other limbs. In contrast to the more common limb-onset type, bulbar-onset ALS initially
impacts speech and swallowing. A third onset type, thoracic, initially impacts respiration.
Approximately 6,000 people in the U.S. are diagnosed annually with ALS. In the U.S., ALS incidence is 2/100,000, with
prevalence of approximately 20,000 individuals. Mean age of onset is 55 years and ranges between 40 and 70, with occasional onset in adolescence and young adulthood. ALS is slightly more predominant in men, but incidence rates are more
comparable across genders in later-onset cases. The duration between symptom onset and diagnosis is approximately 12
months, and average survival time is 3 years from the time of diagnosis. Risk factors are unknown but likely reflect a combination of genetic and environmental factors. Only 10% of all ALS cases are familial, although new genetic mutations are
being discovered with regularity.
Although ALS was once considered a pure neuromuscular condition, a wide range of cognitive and behavioral changes
occur in people with ALS which have important prognostic implications. Up to one-half of people with ALS demonstrate
changes in cognition or behavior, with 15% meeting criteria for dementia, and specifically, frontotemporal dementia (FTD)
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
doi:10.1093/arclin/acx089 Advance Access publication on 28 September 2017
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
907
(Lomen-Hoerth et al., 2003; Ringholz et al., 2005). Region of motor disease onset does not predict who develops cognitive
and behavioral impairment. The presence of FTD or executive dysfunction significantly impacts survival, reducing mean survival time by 12 months. The presence of behavioral symptoms like severe apathy also negatively impacts survival to a significant extent (Caga et al., 2016).
Cognitive and behavioral symptoms can begin prior to motor disease onset, or can develop concurrently or after motor
neuron denervation. Although the behavioral variant of FTD (bvFTD) is most commonly reported in ALS, other FTD variants
(e.g., semantic dementia, progressive non-fluent aphasia) have been documented in ALS (M. Grossman et al., 2008). The estimated interval between the onset of FTD and the diagnosis of ALS ranges from less than 2 years to more than 7 years.
Median survival from disease onset for ALS-FTD patients ranges from 2 to 3 years, which is shorter than survival rates for
bvFTD without ALS (6 years on average) (Lillo, Garcin, Hornberger, Bak, & Hodges, 2010).
Accurate neuropsychological evaluation directly informs symptom management, treatment decisions, education, and scientific discovery. For individuals with ALS and cognitive/behavioral impairment, neuropsychologists have the potential to make
a profound impact related to determination of decisional capacity and end of life care. Neuropsychological assessment can
also provide reassurance when dementia is ruled out. Because of this, accurate and informed neuropsychological assessment
is crucial.
Neuropathology
The general neuropathology of ALS is distinctive (Saberi, Stauffer, Schulte, & Ravits, 2015). Importantly, neuropathological findings are discovered along the entire neuro-axis, including the brain, brainstem motor nuclei, cranial nerves, and spinal
cord. In the spinal cord, hallmark features of disease include atrophy of the anterior horn cells, corresponding sclerosis of the
spinal cord lateral columns, and even atrophy of spinal nerve endings innervating muscles. In the brain and spinal cord,
Bunina bodies are present. The brain is uniquely compromised by the loss of Betz cells in motor cortex, ubiquinated cytoplasmic inclusions composed of TDP-43, atrophy in the frontal and temporal cortices, atrophy of the corticospinal tract, and
generalized loss of white matter volume.
Ubiquitin-positive inclusions are found in the neurons, and occasionally the glial cells, of individuals with ALS. In ALS,
these inclusions are uniquely distributed in the frontal cortex, temporal cortex, hippocampus, and striatum at different stages
of disease progression. Importantly, these inclusions are negative for tau, alpha-synuclein, and other markers of neurodegeneration. TDP-43 is the main component of these ubiquinated inclusions and is uniquely found in people with ALS as well as
people with FTD. Although there are different neuropathological etiologies of FTD, a major portion of FTD cases are characterized by ubiquitin-positive, tau-negative inclusions (also known as Frontal Temporal Lobar Degeneration—Ubiquinated, or
FTLD-U). In 2006, this discovery scientifically linked ALS and FTLD-U, leading to a new taxonomic designation now
known as the TDP-43 proteinopathies (Neumann et al., 2006). Despite various nuances to the clinical presentations, TDP-43
proteinopathies commonly involve loss of nuclear TDP-43 and the formation of pathological aggregates in cytoplasm. The
presence of TDP-43 inclusions is not pathognomic for ALS or FTLD-TDP-43. In fact, such inclusions can be observed in
people with Alzheimer’s dementia, Lewy Body Disease, Guamanian Parkinson’s dementia complex, chronic traumatic
encephalopathy, and more generalized neurodegeneration. It is quite possible that the aggregation and mis-folding of TDP-43
occurs as a natural consequence of the healthy aging process. It is the specific distribution of TDP-43 inclusions in ALS and
FTLD that is relevant and linked to specific clinical presentations and clinical phenotypes.
Almost 90% of ALS cases are sporadic, or non-hereditary, but at least 10% of cases are familial (fALS). The most common mutations identified in familial ALS include SOD-1 TARDP/TDP-43 mutation, FUS (5% of fALS cases), and C9ORF72
repeat expansions. In fALS cases, neuropathological changes with disease progression are somewhat distinctive. For instance,
individuals with SOD-1 mutations have demonstrated greater lower motor neuron than upper motor neuron neurodegeneration. Individuals with fALS and TARDP/TDP-43 mutation appear to have a greater number of pre-inclusions than occur in
sporadic cases of ALS. FUS mutation carriers account for cases of FTLD-U that are TDP-43 negative (Mackenzie et al.,
2010). And finally, C9ORF72 repeat expansion carriers demonstrate TDP-43 pathology seen in other cases of ALS, but also
have highly specific ubiquitin-positive, p62 positive pathology that is TDP-43 negative. This very specific neuropathological
feature leads to dipeptide repeat protein generation most abundant in the cerebellum, hippocampus, and neocortex
(Mackenzie, Frick, & Neumann, 2014). The cerebellar burden of pathology appears to be unique to C9ORF72 repeat expansion carriers, be they individuals with familial or sporadic ALS.
908
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
A Word About ALS Variants and Neuropathology
ALS is a clinical diagnosis contingent upon the presence of both upper and lower motor neuron signs and symptoms.
Variants of ALS, with exclusively upper or lower motor neuron involvement include primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA). PLS is characterized by the presence of upper motor neuron signs and symptoms and the
absence of lower motor neuron signs and symptoms. The same neuropathological characteristics exist in PLS and ALS, but
the distribution of the neuropathological burden typically differs in intensity and location. For example, whereas the greatest
demyelination in ALS appears to occur in the superior frontal gyrus, the greatest demyelination in PLS appears in the corpus
callosum. PMA is diagnosed when an individual demonstrates lower motor neuron signs and symptoms in the absence of
upper motor signs and symptoms. Individuals with PMA that are studied at autopsy frequently present with inclusions positive for ubiquitin, TDP-43, and FUS. Despite, the fact that lower motor neuron clinical symptoms define the presentation of
PMA, neuropathological studies have demonstrated degeneration in the corticospinal tract of individuals with PMA (Ince
et al., 2003). Thus, ALS neuropathology has been observed in PMA, even in the absence of upper motor neuron clinical
symptoms. Taken together, these data suggest that ALS, PLS, and PMA may represent different stages or pathological trajectories of the same continuum. Please note that the upcoming discussion of the cognitive and behavioral features of ALS is
inclusive of cases of PLS and PMA.
Cognitive/Neuropsychological Features of ALS
Given the neuropathological and radiological evidence of frontal and temporal lobe pathology in ALS, it is logical to
expect neuropsychological deficits in this population. A recent revision of the diagnostic criteria for frontotemporal spectrum
disorders in ALS was published in 2017 (Strong et al., 2017), and Table 1 presents the core criteria. These primarily focus on
the detection of behavioral disorders, and executive/language impairment, however; clinical and scientific discovery is ongoing, and the diagnostic criteria recognize that other cognitive domains may be important to evaluate, with documentation of
function at different stages of disease progression. The presentation of cognitive and behavioral symptoms in ALS can be
very heterogeneous and the core diagnostic criteria reflect this. An individual with ALS can have cognitive impairment without meeting criteria for dementia (ALSci), behavioral impairment without meeting criteria for dementia (ALSbi), cognitive
and behavioral impairments without meeting criteria for dementia (ALScbi), or features of ALS and dementia (ALS-FTD).
Below, we describe the literature of cognitive and behavioral symptoms in ALS in detail.
Executive Dysfunction
Phonemic verbal fluency is the hallmark of executive dysfunction in ALS, and is seen early in the disease (Abrahams
et al., 2000, 2004). Fluency dysfunction in ALS correlates with dorsolateral prefrontal cortex dysfunction, may be more
severe in patients with bulbar palsy, and associates with ocular abnormalities (Donaghy et al., 2009). The dysfunction remains
detectable even when motor slowing and dysarthria are controlled for, and is also documented on written verbal fluency measures. Multiple studies have confirmed deficits in phonemic fluency, making this an accepted indicator of cognitive dysfunction in demented and non-demented individuals with ALS.
Other executive-type deficits have been reliably identified on standard assessments measuring attention monitoring and
switching, working memory, cognitive flexibility, and mental control (Evans et al., 2015; Ringholz et al., 2005). People with
ALS may make more errors and take longer to learn new rules on the Wisconsin Card Sorting Test, for example (Lange et al.,
2016). Similar impairments have been shown on other card sorting concept formation tasks such as Delis Kaplan Executive
Function System Card Sorting Test (Libon et al., 2012). Individuals with ALS perform poorly compared to healthy individuals on the Iowa Gambling Task (Girardi, Macpherson, & Abrahams, 2011); the poor performance suggests that individuals
with ALS either fail to learn or fail to execute an effective approach. Other ALS studies employing ecologically valid measures of executive functions demonstrate deficits in reasoning and coordinating rules (Stukovnik, Zidar, Podnar, & Repovs,
2010).
Impairments in social cognition are integral to the diagnosis of FTD, and recent studies of people with ALS also detect
dysfunction in this domain. A meta-analysis (Beeldman et al., 2016) identified social cognition as a significant deficit within
the cognitive profile of ALS. A recent study of people with ALS and no dementia (Andrews, Staios, Howe, Reardon, &
Fisher, 2017) detected impairments in complex facial affect recognition, affective prosody recognition, and cross-modal integration. The later deficit correlated with performance on executive measures, but the majority of results were not explained by
cognitive impairment, mood, or disease severity. A particular deficit in processing negative facial emotions may exist
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
909
Table 1. Revised consensus criteria for the diagnosis of frontotemporal spectrum disorders in ALS (Strong et al., 2017)
Diagnosis
Criteria
ALS Cognitive
Impairment ALSci
Evidence of either executive dysfunction (including social cognition), or
Abrahams et al. (2000)
language dysfunction, or a combination of the two.
– Executive impairment is defined as: Impaired verbal (letter) fluency, OR,
impairment on two other non-overlapping measures of executive
functions (which may include social cognition). Fluency testing must
control for motor and/or speech impairments to be valid.
– Language this impairment is not solely explained by verbal fluency
deficits
Presence of apathy with or without other behavioral change,
Rascovsky et al. (2011)
OR
At least two non-overlapping supportive diagnostic features of behavioral
variant FTD outlined by Rascovsky et al.:
– disinhibition
– loss of sympathy and empathy
– perseverative, stereotyped or compulsive behavior
– hyperorality/dietary change
– loss of insight
– psychotic symptoms (e.g. somatic delusions, hallucinations, irrational
beliefs)
Patients meeting criteria for both ALSci and ALSbi without meeting
criteria for ALS-FTD
ALS Behavioral
Impairment ALSbi
ALS Cognitive and
Behavioral
Impairment ALScbi
ALS-Frontotemporal
Dementia ALS-FTD
FTD-MND like
ALS-Parkinsonismdementia-complex
Evidence of progressive deterioration of behavior and/or cognition by
observation or history, AND
Presence of at least 3 of the behavioral/cognitive symptoms outlined by
Rascovsky et al.
OR
The presence of at least 2 of those behavioral/cognitive symptoms,
together with loss of insight and/or psychotic symptoms
OR
The presence of language impairment meeting criteria for semantic
dementia/semantic variant PPA or non-fluent variant
A neuropathological diagnosis in which FTLD is the primary diagnosis
and concomitant neuropathological evidence of motor neuron
degeneration, but insufficient to be classified as ALS
ALS concurrent with dementia and/or Parkinsonism occurring in
hyperendemic foci of the Western Pacific
Key references
“Clinical and neuropathological criteria for
frontotemporal dementia. The Lund and Manchester
Groups” (1994)
Rascovsky et al. (2011)
Gorno-Tempini et al. (2011)
(Palmieri et al., 2010) which may be specific to individuals with ALS-FTD but not those with ALS and no dementia (Savage
et al., 2014). Studies using the Judgment of Preference Task (Girardi et al., 2011) demonstrate difficulty interpreting the eye
gaze direction of others. Similar impairments are observed on tests evaluating Theory of Mind. In one study, approximately
30% of people with ALS but no dementia were impaired at detecting a faux pas (Meier, Charleston, & Tippett, 2010).
Insight has been infrequently studied, but preliminary evidence suggests that, as a group, non-demented people with ALS
retain insight into cognitive and behavioral changes, in contrast to people with ALS-FTD who demonstrate profound lack of
awareness (Woolley, Moore, & Katz, 2010).
Language
Language deficits have received less attention until recently, despite early studies which detected a correlation between
cognitive impairment and clinical measures of word-finding and phrase-length (Ringholz et al., 2005). The clinical relevance
of language deficits in ALS has been minimized due to the perceived confounds of dysarthria, respiratory insufficiency, and
motor dysfunction. However, language dysfunction is at least as common as executive dysfunction in ALS, and can co-occur
with executive deficits or exist independently (Taylor et al., 2013). An estimated 35–40% of people with ALS demonstrate
clinically significant language dysfunction (Taylor et al., 2013).
Syntactic processing deficits may be a predominant feature of language dysfunction in ALS (Tsermentseli et al., 2015).
Verb naming and action verb processing deficits are consistently documented (Bak, O’Donovan, Xuereb, Boniface, &
910
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
Hodges, 2001; Papeo et al., 2015) which associate with atrophy in the dorsolateral prefrontal cortex and motor cortex (Bak
et al., 2001; Grossman et al., 2008; York et al., 2014). Semantic and verbal paraphasic errors have also been detected
(Roberts-South, Findlater, Strong, & Orange, 2012; Tsermentseli et al., 2015). In a study of clinical differences across FTD
genotypes, 78% of patients with the ALS-FTD C9ORF72 mutation demonstrated a naming disorder, and a smaller majority
displayed difficulty generating context-specific and relevant words within conversations (Snowden et al., 2015). Grammatical
errors dissociate from motor and respiratory dysfunction and executive dysfunction, suggesting a continuum between ALS
and non-fluent/agrammatic primary progressive aphasia (Ash et al., 2015). Examples of grammatical errors can include
incomplete utterances, omission of determiners, and verb phrase errors (Ash et al., 2015). Other language deficits detected in
ALS include difficulty establishing and staying on topic in conversation (Bambini et al., 2016), difficulty relaying the main
topic of conversation (Ash et al., 2015), and fewer content or information words in proportion to total word production (Ash
et al., 2014; Bambini et al., 2016). Deficits in language comprehension are not confounded by impaired speech production,
and syntactic comprehension deficits are present in 28–72% of individuals with ALS (Kamminga et al., 2016; Yoshizawa
et al., 2014).
Memory
Memory impairment in ALS typically occurs concurrently with other cognitive deficits (Phukan et al., 2012), and does not
appear to impact survival (Elamin et al., 2011). A 2015 meta-analysis (Beeldman et al., 2016) showed a small effect size for
delayed verbal memory and executive dysfunction, with larger effect sizes for other domains (e.g., fluency, language, and
social cognition). Many researchers argue that executive dysfunction underlies and explains much of the variance in memory
impairment (Beeldman et al., 2016; Christidi, Zalonis, Smyrnis, & Evdokimidis, 2012; Hanagasi et al., 2002; Machts et al.,
2014; Mantovan et al., 2003; Massman et al., 1996). Memory deficits are detected in non-demented individuals with ALS;
these changes correlate with gray matter hippocampal volumes (Raaphorst et al., 2015) and cognitively impaired patients may
demonstrate declines in verbal recall over time (Elamin et al., 2013). Qualitative differences in memory profiles distinguish
people with ALS from people with Mild Cognitive Impairment—Amnestic subtype (Machts et al., 2014). A population based
study (Phukan et al., 2012) suggests that Alzheimer’s disease is less common (1.9%) than FTD (13.8%), among people with
ALS. The recently revised diagnostic consensus criteria do not include isolated memory impairment as a criterion for the diagnosis of ALS cognitive impairment (ALSci).
Neuropsychiatric Features of ALS
Depression
Relatively high rates of depression are seen in neurologic diseases such as Parkinson’s disease, MS, and stroke. Naive observers assume that people diagnosed with ALS should be depressed due to the unrelenting nature of the terminal illness, but
in fact, rates of clinically diagnosable depression are consistent with the general population and healthy controls (Atassi et al.,
2011; Grossman, Woolley-Levine, Bradley, & Miller, 2007; Jelsone-Swain et al., 2012; Rabkin et al., 2015). Depression in
ALS tends to be seen early in the disease around the time of diagnosis. Individuals who experience a longer time interval
between symptom onset and ALS diagnosis are at increased risk for depression (Caga, Ramsey, Hogden, Mioshi, & Kiernan,
2015). Rabkin and colleagues (2015) cite that among individuals with late-stage ALS, 9% had symptoms consistent with
major depression, and another 10% had symptoms consistent with minor depression. Depression is rare in ALS-FTD patients,
assumingly due to the lack of insight and pronounced apathy. It is worth noting that caregivers may misperceive apathy in a
person with ALS as a sign of severe depression.
Apathy
Mild behavior change predates motor dysfunction in classical ALS, but does not impact survival (Mioshi et al., 2014).
Mild behavioral abnormalities can co-occur with cognitive impairment in ALS or occur in isolation (Witgert et al., 2010).
The most common behavioral abnormality in ALS is apathy, which is detected in 40–80% of patients and dissociates from
depression, respiratory dysfunction, and motor disease severity (Grossman et al., 2007; Lillo, Mioshi, Zoing, Kiernan, &
Hodges, 2011).
When apathy is severe, it serves as an independent, negative prognostic indicator. For people with ALS who have severe
apathy, survival time is reduced, by an average of 15 months compared to similar patients with mild apathy (Caga et al.,
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
911
2016). In this study, depression with demoralization was not associated with degree of apathy. A diffuse-tensor imaging study
detected a significant fractional anisotropy in the right anterior cingulate which correlated with caregiver reports of apathy
change, and dissociated from disease progression biomarkers in the motor cortex (Woolley, Zhang, Schuff, Weiner, & Katz,
2011). Apathy appears to be the initial symptom in ALS-FTD and may best discriminate between early ALS-FTD and classical FTD (Hsieh et al., 2016).
Pseudobulbar Affect
Also referred to as emotional lability, this symptom is common in ALS, particularly for those with greater bulbar involvement. Spontaneous crying or laughing episodes of pseudobulbar affect (PBA) can be difficult to control and may occur without provocation. For those who are tearful, caregivers may mistakenly describe the patient as depressed. Careful questioning
can help differentiate depressive symptoms from PBA.
Loss of Empathy
ALS caregivers report high rates of self-centeredness in ALS (Hsieh et al., 2016). This could be due to the fact that individuals with ALS do not process emotion as effectively as healthy individuals, negatively impacting social processing (Girardi
et al., 2011). People with ALS also have difficulty inferring the mental state of others and inhibiting egocentric responses.
These social and emotional deficits appear to dissociate from classical executive dysfunction (Girardi et al., 2011). Emotional
empathy in ALS is reduced compared to samples of neurologically healthy people, and this associated with reduced gray–
white matter density in the anterior cingulate and right inferior frontal gyrus (Cerami et al., 2014). However, it has also been
suggested that medial prefrontal and inferior frontal gyrus regions associate with inhibition of empathy and increased selfperspective taking (Rice & Redcay, 2015).
Disinhibition
Disinhibition has been documented in ALS and ALS-FTD, although to-date, it is less frequently documented than other
behavioral symptoms. If present, it is most often noticed in FTD prior to ALS onset. This may be due to the fact that apathy
becomes predominant over time and overwhelms any evidence of inappropriateness or lack of inhibition. Additionally, the
motor disease of ALS may preclude a disinhibited person’s ability to express aberrant behavioral due to paralysis or mutism.
The presence of disinhibition may also be a function of genotype. Compared to other genetically-based FTD groups, ALSFTD individuals with the ALS specific genotype (C9ORF72) presented clinically as more socially appropriate and warm than
classic bvFTD individuals without ALS (Snowden et al., 2015).
ALS-FTD
The behavioral features of FTD are well described in current diagnostic criteria (Rascovsky et al., 2011). With an insidious
onset and gradual progression, pure FTD can appear much like a psychiatric disorder with pronounced personality change,
deficits in social comportment, language dysfunction, and a host of behavioral deficits.
Certain clinical characteristics of people with ALS-FTD differ from those with classic FTD. As previously mentioned,
early apathy may be a unique indicator of ALS-FTD but not pure FTD (Hsieh et al., 2016), and people with ALS-FTD may
present as more socially appropriate than individuals with FTD and no ALS. Fewer dietary changes, specifically sweets preferences, occur in ALS-FTD patients with the C9ORF72 genotype (Snowden et al., 2012).
Some individuals with the C9ORF72 mutations have a documented history of psychosis. Thirty-eight percentage of patients with the C9ORF72 mutation had a history of significant psychotic symptoms pre-dating the onset of either ALS or
FTD, compared to less than 4% of FTD patients without the mutation (Snowden et al., 2012). Somatoform delusions are not
seen in other genetically-based FTD groups. An associated increased incidence of complex repetitive behaviors is seen in this
cohort, which seems to be linked to delusional thinking. The presence of psychotic symptoms is now a feature of the current
diagnostic criteria for ALS-FTD, assuming the symptoms are not better explained by a chronic psychiatric disorder.
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
912
Table 2. Practice recommendations in ALS
Objective
References
Test selection
Strong et al.
Executive function and language function impairments are the
(2017)
most cited impairments
Woolley, York,
et al. (2010)
Abrahams et al.
(2014)
Abrahams et al. Valid assessment methodological control for motor limitations
(2000)
and challenges
Motor symptom
control
Longitudinal
evaluation
Document
genotypephenotype
associations
Findings
Burkhardt,
Rate of progression of cognitive and behavioral impairment
Neuwirth and
remains unknown and it is unclear the degree to which this
Weber (2017)
may be associated with progression of motor symptoms
Gillingham
et al. (2016)
Strong et al.
Documented genotype-phenotype associations lead to advancing
(2017)
scientific and clinical understanding (i.e., C9ORF72)
Recommendation
Screens and neuropsychological evaluations should
include measures of verbal fluency, behavior
change, and mental flexibility
Screens such as the ALS-CBS and the ECAS were
created specifically for use in ALS and are
encouraged
Include measures like Abrahams Verbal Fluency
that control for motor limitations of ALS
Allow written or oral responses
Repeat evaluation every 6 months and compare to
baseline data
Document any history of MND, dementia, or
cognitive disorder from the family history
MND, motor neuron disease.
Neuropsychological Assessment Strategy and Differential Diagnosis
Neuropsychological assessment of a person with ALS requires unique consideration of several issues. These may include
test selection, awareness of motor disease severity, possible modifications to standardization procedures, test-retest intervals,
and limitations to data interpretation based on differential diagnosis and available normative samples. Practice recommendations related to most of these issues are highlighted in Table 2. Tests of executive function and language should be a priority
in the evaluation, to include phonemic fluency, semantic fluency, syntax processing, spelling, mental flexibility, judgment,
reasoning, and inhibitory control. Although less common, some people with ALS develop amnestic features of difficulties
with learning and retrieval as a manifestation of the cognitive impairment.
A person with ALS may be unable to write or unable to speak as a function of motor symptoms. Tests must be selected
knowing what response modality is possible, and with the knowledge that response modality may change over time, with
symptom progression. An individual may be able to speak early in the course of illness, but become mute as a function of bulbar symptom progression in the future. If longitudinal data collection is a goal, tests that can be answered with written, pointing, and oral responses should be considered. Further, strong consideration should be given to tests such as Abrahams Written
Verbal Fluency, and similar measures, which provide some form of methodological control for motor impairment in the evaluation of cognitive impairment symptoms. The person with ALS will be fatigable regardless of how symptoms evolve.
Unlike stroke or brain injury populations, for which cognitive stamina can be built up with incrementally longer evaluations
or interventions, the opposite is true in ALS. Evaluations and interventions must be focused and brief in administration time.
ALS survival time is much shorter than survival time of a person with Mild Cognitive Impairment, Alzheimer’s dementia,
Lewy Body Dementia, or even Frontal Temporal Dementia without Motor Neuron Disease. As a function of this, documenting cognitive trajectory of symptoms requires more frequent re-test intervals than the conventional 1-year follow-up that other
cognitive syndromes utilize. For instance, re-testing after 6 months could be quite important. There can be tremendous change
in a person’s function within 6 months, and there is great utility for the longitudinal neuropsychological evaluation to update
functional recommendations for the person with ALS, as illness progresses.
Prior to making any causative associations between ALS/MND and cognitive symptoms detected on neuropsychological
evaluation, differential diagnosis should be considered. Specific to ALS, clinicians must rule out the possibility of a preexisting cognitive syndrome or disorder, such as prior stroke, developmental challenge, ischemic injury (secondary to oxygen
desaturation or apnea), or longstanding patterns of strengths and weaknesses. Depression, adjustment to diagnosis, and adjustment to disability may be current issues for a person with ALS, and therefore, the neuropsychologist must carefully evaluate
and consider the contributions of these psychological factors to the conceptualization of cognitive status. The most effective
neuropsychological evaluation of the person with ALS should include behavioral observations of the person, as well as selfand informant- reports of emotional status. These data should enter into the diagnostic conceptualization of each individual to
the best of the neuropsychologist’s ability. It is very important to document the presence or absence of insight in the person
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
913
with ALS. Diminished self-awareness, or anosognosia, is importantly distinguished from psychological denial. The absence
or restriction of self-awareness bears important weight on where to emphasize the focus of interventions. When selfawareness is still present to any degree, the person with ALS and cognitive/behavioral impairment can anticipate challenges
in function or daily activities, and therefore interventions can be directly introduced to the person with ALS. Reduced or
absent self-awareness can negatively influence symptom management, disease management, premorbid advanced directives,
and team relationships. The anosognosia can also exacerbate caregiver burden.
Providers working with people who have ALS should consider screening tools that have been designed specifically for use
in ALS and empirically validated in samples of people with ALS. It behooves the clinician to use cognitive and behavioral
screening tools specifically designed for people with ALS rather than trying to adapt existing measures to the person with
ALS, particularly given the complexities of case conceptualization. In recent years, more and more cognitive screening tools
have been proposed for use in ALS. At the time of this publication, the Edinburgh Cognitive and Behavioral ALS Screen
(ECAS) (Abrahams, Newton, Niven, Foley, & Bak, 2014) and the ALS Cognitive Behavioral Screen (ALS-CBS) (Woolley,
York, et al., 2010) have the most validation data. As such, these two screening tools are specifically referenced in the most
recent diagnostic criteria for frontotemporal cognitive impairment in ALS(Strong et al., 2017).
Laboratory, Radiographic, and Genetic Associations
A combination of laboratory data, radiographic data, and even genetic background reveals ALS and potential cognitive
and behavioral impact of symptoms in ALS. EMG, modified barium swallowing studies, pulmonary function tests, motor
speech evaluations, and the neurologic exam are used to initially assess for the presence of upper motor neuron, lower motor
neuron, or cranial nuclei dysfunction. Brain and spinal cord MRI studies can help also to evaluate the presence of atrophy
that is characteristic to ALS. Support for an FTD diagnosis may come from MRI findings of frontal/temporal lobe atrophy,
although many people with ALS cannot tolerate scanning due to the risk of aspiration, choking or respiratory distress while
supine. Generally, imaging evidence is supportive but not diagnostic, and a negative scan does not rule out FTD, non-FTD
dementia, ALSci, or ALSbi.
Intervening and Treating the Person with ALS/MND
The cognitive and behavioral challenges of ALS are manifestations of the primary neurodegenerative disease process.
Interventions and treatments are focused on symptom management, education of the person with ALS and his/her family, and
the identification of compensatory aids, approaches, and strategies. As mentioned earlier, it is important to know the degree to
which self-awareness is present or absent in the person with ALS. This guides the direction of any intervention or treatment.
When self-awareness is present, and/or the person with ALS retains cognitive skills, he/she can make use of voicing applications on a tablet or smartphone, traditional alternative augmentative communication devices, dry erase boards, and even functional communication boards. If self-awareness is restricted or absent for the person with ALS, interventions and treatments
may be focused on modifying physiological factors that contribute to the symptom, or to the environment, including caregivers, surrounding the affected person. In PBA, the FDA has approved the use of Nuedexta, a dextromethorphan-quinidine
sulfate compound that attenuates disproportionate laughing, crying, or increased emotional reactivity. In situations for which
excessive psychomotor agitation, fall risk, impulsive gait or transfers, or disinhibited behavior create challenge, other psychotropic medications such as low-dose SSRIs or even very low dose atypical antipsychotics can be considered.
Most of the time, interventions and treatment in ALS are focused on quality of life and safety. For the person with cognitive and/or behavioral challenges, it is important to identify advanced directives as early as possible in the course of disease.
Caregivers, family members, and even providers on the team should be educated about appropriate expectations for the person
with ALS. When a caregiver or team member is reporting that a person with ALS/MND is having difficulty following or responding to recommendations, the neuropsychologist can use information from the cognitive and behavioral evaluation to
educate team members about the most effective ways to work with the person, using his/her strengths or environmental
strengths to meet challenges. Arguably, the neuropsychological evaluation of the person with ALS/MND provides some of
the most powerful data for informing interventions and addressing functional recommendations.
Conflict of interest
None declared.
914
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
References
Abrahams, S., Goldstein, L. H., Simmons, A., Brammer, M., Williams, S. C., Giampietro, V., et al. (2004). Word retrieval in amyotrophic lateral sclerosis: a
functional magnetic resonance imaging study. Brain, 127, 1507–1517. doi:10.1093/brain/awh170.
Abrahams, S., Leigh, P. N., Harvey, A., Vythelingum, G. N., Grise, D., & Goldstein, L. H. (2000). Verbal fluency and executive dysfunction in amyotrophic
lateral sclerosis (ALS). Neuropsychologia, 38, 734–747.
Abrahams, S., Newton, J., Niven, E., Foley, J., & Bak, T. H. (2014). Screening for cognition and behaviour changes in ALS. Amyotrophic Lateral Sclerosis
& Frontotemporal Degeneration, 15, 9–14. doi:10.3109/21678421.2013.805784.
Andrews, S. C., Staios, M., Howe, J., Reardon, K., & Fisher, F. (2017). Multimodal emotion processing deficits are present in amyotrophic lateral sclerosis.
Neuropsychology. doi:10.1037/neu0000323.
Ash, S., Menaged, A., Olm, C., McMillan, C. T., Boller, A., Irwin, D. J., et al. (2014). Narrative discourse deficits in amyotrophic lateral sclerosis.
Neurology, 83, 520–528. doi:10.1212/WNL.0000000000000670.
Ash, S., Olm, C., McMillan, C. T., Boller, A., Irwin, D. J., McCluskey, L., et al. (2015). Deficits in sentence expression in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 16, 31–39. doi:10.3109/21678421.2014.974617.
Atassi, N., Cook, A., Pineda, C. M., Yerramilli-Rao, P., Pulley, D., & Cudkowicz, M. (2011). Depression in amyotrophic lateral sclerosis. Amyotrophic
Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 12, 109–112. doi:10.3109/
17482968.2010.536839.
Bak, T. H., O’Donovan, D. G., Xuereb, J. H., Boniface, S., & Hodges, J. R. (2001). Selective impairment of verb processing associated with pathological
changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. Brain, 124, 103–120.
Bambini, V., Arcara, G., Martinelli, I., Bernini, S., Alvisi, E., Moro, A., et al. (2016). Communication and pragmatic breakdowns in amyotrophic lateral sclerosis patients. Brain and Language, 153-154, 1–12. doi:10.1016/j.bandl.2015.12.002.
Beeldman, E., Raaphorst, J., Klein Twennaar, M., de Visser, M., Schmand, B. A., & de Haan, R. J. (2016). The cognitive profile of ALS: a systematic review
and meta-analysis update. Journal of Neurology, Neurosurgery, and Psychiatry, 87, 611–619. doi:10.1136/jnnp-2015-310734.
Burkhardt, C., Neuwirth, C., & Weber, M. (2017). Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis
Screen (ECAS): lack of practice effect in ALS patients? Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 18, 202–209. doi:10.1080/
21678421.2017.1283418.
Caga, J., Ramsey, E., Hogden, A., Mioshi, E., & Kiernan, M. C. (2015). A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis.
Palliative & Supportive Care, 13, 1019–1024. doi:10.1017/S1478951514000881.
Caga, J., Turner, M. R., Hsieh, S., Ahmed, R. M., Devenney, E., Ramsey, E., et al. (2016). Apathy is associated with poor prognosis in amyotrophic lateral
sclerosis. European Journal of Neurology : The Official Journal of the European Federation of Neurological Societies, 23, 891–897. doi:10.1111/ene.
12959.
Cerami, C., Dodich, A., Canessa, N., Crespi, C., Iannaccone, S., Corbo, M., et al. (2014). Emotional empathy in amyotrophic lateral sclerosis: a behavioural
and voxel-based morphometry study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 15, 21–29. doi:10.3109/21678421.2013.785568.
Christidi, F., Zalonis, I., Smyrnis, N., & Evdokimidis, I. (2012). Selective attention and the three-process memory model for the interpretation of verbal free
recall in amyotrophic lateral sclerosis. Journal of the International Neuropsychological Society : JINS, 18, 809–818. doi:10.1017/S1355617712000562.
Donaghy, C., Pinnock, R., Abrahams, S., Cardwell, C., Hardiman, O., Patterson, V., et al. (2009). Ocular fixation instabilities in motor neurone disease. A
marker of frontal lobe dysfunction? Journal of Neurology, 256, 420–426. doi:10.1007/s00415-009-0109-x.
Elamin, M., Bede, P., Byrne, S., Jordan, N., Gallagher, L., Wynne, B., et al. (2013). Cognitive changes predict functional decline in ALS: a population-based
longitudinal study. Neurology, 80, 1590–1597. doi:10.1212/WNL.0b013e31828f18ac.
Elamin, M., Phukan, J., Bede, P., Jordan, N., Byrne, S., Pender, N., et al. (2011). Executive dysfunction is a negative prognostic indicator in patients with
ALS without dementia. Neurology, 76, 1263–1269. doi:76/14/1263 [pii]: 10.1212/WNL.0b013e318214359f.
Evans, J., Olm, C., McCluskey, L., Elman, L., Boller, A., Moran, E., et al. (2015). Impaired cognitive flexibility in amyotrophic lateral sclerosis. Cognitive
and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology, 28, 17–26. doi:10.1097/WNN.0000000000000049.
Gillingham, S. M., Yunusova, Y., Ganda, A., Rogaeva, E., Black, S. E., Stuss, D. T., et al. (2017). Assessing cognitive functioning in ALS: A focus on frontal lobe processes. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 18, 182–192. doi:10.1080/21678421.2016.1248977.
Girardi, A., Macpherson, S. E., & Abrahams, S. (2011). Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology, 25,
53–65. doi:10.1037/a0020357.
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., et al. (2011). Classification of primary progressive aphasia and its
variants. Neurology, 76, 1006–1014. doi:10.1212/WNL.0b013e31821103e6.
Grossman, A. B., Woolley-Levine, S., Bradley, W. G., & Miller, R. G. (2007). Detecting neurobehavioral changes in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 8, 56–61. doi:10.
1080/17482960601044106.
Grossman, M., Anderson, C., Khan, A., Avants, B., Elman, L., & McCluskey, L. (2008). Impaired action knowledge in amyotrophic lateral sclerosis.
Neurology, 71, 1396–1401. doi:10.1212/01.wnl.0000319701.50168.8c.
Hanagasi, H. A., Gurvit, I. H., Ermutlu, N., Kaptanoglu, G., Karamursel, S., Idrisoglu, H. A., et al. (2002). Cognitive impairment in amyotrophic lateral sclerosis: evidence from neuropsychological investigation and event-related potentials. Brain Research. Cognitive brain research, 14, 234–244.
Hsieh, S., Caga, J., Leslie, F. V., Shibata, M., Daveson, N., Foxe, D., et al. (2016). Cognitive and behavioral symptoms in ALSFTD: detection, differentiation,
and progression. Journal of Geriatric Psychiatry and Neurology, 29, 3–10. doi:10.1177/0891988715598232.
Ince, P. G., Evans, J., Knopp, M., Forster, G., Hamdalla, H. H., Wharton, S. B., et al. (2003). Corticospinal tract degeneration in the progressive muscular
atrophy variant of ALS. Neurology, 60, 1252–1258.
Jelsone-Swain, L., Persad, C., Votruba, K. L., Weisenbach, S. L., Johnson, T., Gruis, K. L., et al. (2012). The Relationship between depressive symptoms,
disease state, and cognition in amyotrophic lateral sclerosis. Frontiers in Psychology, 3, 542. doi:10.3389/fpsyg.2012.00542.
Kamminga, J., Leslie, F. V., Hsieh, S., Caga, J., Mioshi, E., Hornberger, M., et al. (2016). Syntactic comprehension deficits across the FTD-ALS continuum.
Neurobiology of Aging, 41, 11–18. doi:10.1016/j.neurobiolaging.2016.02.002.
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
915
Lange, F., Lange, C., Joop, M., Seer, C., Dengler, R., Kopp, B., et al. (2016). Neural correlates of cognitive set shifting in amyotrophic lateral sclerosis.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology, 127, 3537–3545. doi:10.1016/j.clinph.2016.09.
019.
Libon, D. J., McMillan, C., Avants, B., Boller, A., Morgan, B., Burkholder, L., et al. (2012). Deficits in concept formation in amyotrophic lateral sclerosis.
Neuropsychology, 26, 422–429. doi:10.1037/a0028668.
Lillo, P., Garcin, B., Hornberger, M., Bak, T. H., & Hodges, J. R. (2010). Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Archives of Neurology, 67, 826–830. doi:10.1001/archneurol.2010.146.
Lillo, P., Mioshi, E., Zoing, M. C., Kiernan, M. C., & Hodges, J. R. (2011). How common are behavioural changes in amyotrophic lateral sclerosis?
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 12, 45–51.
doi:10.3109/17482968.2010.520718.
Lomen-Hoerth, C., Murphy, J., Langmore, S., Kramer, J. H., Olney, R. K., & Miller, B. (2003). Are amyotrophic lateral sclerosis patients cognitively normal?
Neurology, 60, 1094–1097.
The Lund and Manchester Groups. (1994). Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery, and
Psychiatry, 57, 416–418.
Machts, J., Bittner, V., Kasper, E., Schuster, C., Prudlo, J., Abdulla, S., et al. (2014). Memory deficits in amyotrophic lateral sclerosis are not exclusively
caused by executive dysfunction: a comparative neuropsychological study of amnestic mild cognitive impairment. BMC Neuroscience, 15, 83. doi:10.
1186/1471-2202-15-83.
Mackenzie, I. R., Frick, P., & Neumann, M. (2014). The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathologica,
127, 347–357. doi:10.1007/s00401-013-1232-4.
Mackenzie, I. R., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., et al. (2010). Nomenclature and nosology for neuropathologic subtypes of
frontotemporal lobar degeneration: an update. Acta Neuropathologica, 119 (1), 1–4. doi:10.1007/s00401-009-0612-2.
Mantovan, M. C., Baggio, L., Dalla Barba, G., Smith, P., Pegoraro, E., Soraru, G., et al. (2003). Memory deficits and retrieval processes in ALS. European
Journal of Neurology : The Official Journal of the European Federation of Neurological Societies, 10, 221–227.
Massman, P. J., Sims, J., Cooke, N., Haverkamp, L. J., Appel, V., & Appel, S. H. (1996). Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry, 61, 450–455.
Meier, S. L., Charleston, A. J., & Tippett, L. J. (2010). Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic
lateral sclerosis. Brain, 133, 3444–3457. doi:10.1093/brain/awq254.
Mioshi, E., Caga, J., Lillo, P., Hsieh, S., Ramsey, E., Devenney, E., et al. (2014). Neuropsychiatric changes precede classic motor symptoms in ALS and do
not affect survival. Neurology, 82, 149–155. doi:10.1212/WNL.0000000000000023.
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science (New York, N.Y.), 314, 130–133. doi:314/5796/130 [pii]: 10.1126/science.1134108.
Palmieri, A., Naccarato, M., Abrahams, S., Bonato, M., D’Ascenzo, C., Balestreri, S., et al. (2010). Right hemisphere dysfunction and emotional processing
in ALS: an fMRI study. Journal of Neurology, 257, 1970–1978. doi:10.1007/s00415-010-5640-2.
Papeo, L., Cecchetto, C., Mazzon, G., Granello, G., Cattaruzza, T., Verriello, L., et al. (2015). The processing of actions and action-words in amyotrophic lateral sclerosis patients. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 64, 136–147. doi:10.1016/j.cortex.2014.10.007.
Phukan, J., Elamin, M., Bede, P., Jordan, N., Gallagher, L., Byrne, S., et al. (2012). The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a
population-based study. Journal of Neurology, Neurosurgery, and Psychiatry, 83, 102–108. doi:jnnp-2011-300188 [pii]: 10.1136/jnnp-2011-300188.
Raaphorst, J., van Tol, M. J., de Visser, M., van der Kooi, A. J., Majoie, C. B., van den Berg, L. H., et al. (2015). Prose memory impairment in amyotrophic
lateral sclerosis patients is related to hippocampus volume. European Journal of Neurology : The Official Journal of the European Federation of
Neurological Societies, 22, 547–554. doi:10.1111/ene.12615.
Rabkin, J. G., Goetz, R., Factor-Litvak, P., Hupf, J., McElhiney, M., & Singleton, J., Als Cosmos Study, G. (2015). Depression and wish to die in a multicenter cohort of ALS patients. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 16, 265–273. doi:10.3109/21678421.2014.980428.
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: a Journal of Neurology, 134, 2456–2477. doi:10.1093/brain/awr179.
Rice, K., & Redcay, E. (2015). Spontaneous mentalizing captures variability in the cortical thickness of social brain regions. Social Cognitive and Affective
Neuroscience, 10, 327–334. doi:10.1093/scan/nsu081.
Ringholz, G. M., Appel, S. H., Bradshaw, M., Cooke, N. A., Mosnik, D. M., & Schulz, P. E. (2005). Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology, 65, 586–590. doi:10.1212/01.wnl.0000172911.39167.b6.
Roberts-South, A., Findlater, K., Strong, M. J., & Orange, J. B. (2012). Longitudinal changes in discourse production in amyotrophic lateral sclerosis.
Seminars in Speech and Language, 33, 79–94. doi:10.1055/s-0031-1301165.
Saberi, S., Stauffer, J. E., Schulte, D. J., & Ravits, J. (2015). Neuropathology of amyotrophic lateral sclerosis and its variants. Neurologic clinics, 33,
855–876. doi:10.1016/j.ncl.2015.07.012.
Savage, S. A., Lillo, P., Kumfor, F., Kiernan, M. C., Piguet, O., & Hodges, J. R. (2014). Emotion processing deficits distinguish pure amyotrophic lateral
sclerosis from frontotemporal dementia. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 15, 39–46. doi:10.3109/21678421.2013.809763.
Snowden, J. S., Adams, J., Harris, J., Thompson, J. C., Rollinson, S., Richardson, A., et al. (2015). Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 16, 497–505.
doi:10.3109/21678421.2015.1074700.
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M., et al. (2012). Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain, 135, 693–708. doi:10.1093/brain/awr355.
Strong, M. J., Abrahams, S., Goldstein, L. H., Woolley, S., McLaughlin, P., Snowden, J., et al. (2017). Amyotrophic lateral sclerosis—frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 18, 153–174. doi:10.1080/
21678421.2016.1267768.
916
S.C. Woolley, B.K. Rush / Archives of Clinical Neuropsychology 32 (2017); 906–916
Stukovnik, V., Zidar, J., Podnar, S., & Repovs, G. (2010). Amyotrophic lateral sclerosis patients show executive impairments on standard neuropsychological
measures and an ecologically valid motor-free test of executive functions. Journal of Clinical and Experimental Neuropsychology, 32, 1095–1109. doi:10.
1080/13803391003749236.
Taylor, L. J., Brown, R. G., Tsermentseli, S., Al-Chalabi, A., Shaw, C. E., Ellis, C. M., et al. (2013). Is language impairment more common than executive
dysfunction in amyotrophic lateral sclerosis? Journal of Neurology, Neurosurgery, and Psychiatry, 84, 494–498. doi:10.1136/jnnp-2012-303526.
Tsermentseli, S., Leigh, P. N., Taylor, L. J., Radunovic, A., Catani, M., & Goldstein, L. H. (2015). Syntactic processing as a marker for cognitive impairment
in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 17, 69–76. doi:10.3109/21678421.2015.1071397.
Witgert, M., Salamone, A. R., Strutt, A. M., Jawaid, A., Massman, P. J., Bradshaw, M., et al. (2010). Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. European Journal of Neurology, 17, 103–110. doi:10.1111/j.1468-1331.2009.02801.x.
Woolley, S. C., Moore, D. H., & Katz, J. S. (2010). Insight in ALS: awareness of behavioral change in patients with and without FTD. Amyotrophic Lateral
Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 11, 52–56. doi:914239258 [pii]:
10.3109/17482960903171110.
Woolley, S. C., York, M. K., Moore, D. H., Strutt, A. M., Murphy, J., Schulz, P. E., et al. (2010). Detecting frontotemporal dysfunction in ALS: utility of the
ALS Cognitive Behavioral Screen (ALS-CBS). Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research
Group on Motor Neuron Diseases, 11, 303–311. doi:10.3109/17482961003727954.
Woolley, S. C., Zhang, Y., Schuff, N., Weiner, M. W., & Katz, J. S. (2011). Neuroanatomical correlates of apathy in ALS using 4 Tesla diffusion tensor
MRI. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases, 12, 52–58.
doi:10.3109/17482968.2010.521842.
York, C., Olm, C., Boller, A., McCluskey, L., Elman, L., Haley, J., et al. (2014). Action verb comprehension in amyotrophic lateral sclerosis and Parkinson’s
disease. Journal of Neurology, 261, 1073–1079. doi:10.1007/s00415-014-7314-y.
Yoshizawa, K., Yasuda, N., Fukuda, M., Yukimoto, Y., Ogino, M., Hata, W., et al. (2014). Syntactic comprehension in patients with amyotrophic lateral sclerosis. Behavioural Neurology, 2014, 230578. doi:10.1155/2014/230578.
Документ
Категория
Без категории
Просмотров
4
Размер файла
222 Кб
Теги
arclin, 2facx089
1/--страниц
Пожаловаться на содержимое документа